CAML20 Jul 2021 13:47
I've been looking at previous results since they bought SASA, and the strongest I can see are the 2018 Interims. Comparing them with the upcoming H1 results for 2021, metal prices for 2021 are significantly higher than H1 2018, but I don't see the EBITDA figure of $64.6 of HI 2018 being higher in H1 2021, due to higher treatment charges. The big difference is net debt to 30.06.18 was $125 million, and for 30.06.2021 it's $10 million, which the market chooses to ignore. Q3 always has the highest production numbers for CAML's metals, and with prices still strong(even taking into account the various hedges in place) CAML's Q3 should easily be the most profitable in its history. A new treatment charges contract was signed on 01.04.21 which is 30% cheaper than the previous one which should help, along with rapidly falling interest costs. I have a core holding here but have been trading the stock continually. I bought at 274 on April 20 and sold at 286 on April 27, when metal prices were lower than today, and bought another tranche recently at 264, which looks like I won't be selling anytime soon. The share price is mystifying, I note that Covid has spread quite quickly in the regions CAML operates in, but the company said in their most recent trading update there were no cases, so fingers crossed. GLA